Efficacy and Safety of LY2963016 Insulin Glargine in Patients With Type 1 and Type 2 Diabetes Previously Treated With Insulin Glargine

Diabetes, Obesity and Metabolism - United Kingdom
doi 10.1111/dom.12628
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Fasting and Insulin Glargine in Individuals With Type 1 Diabetes

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2004English

Similar Intrapatient Blood Glucose Variability With LY2963016 and Lantus® Insulin Glargine in Patients With Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSII

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2005English

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People With Type 2 Diabetes

Diabetes Technology and Therapeutics
MedicineEndocrinologyMedical Laboratory TechnologyMetabolismDiabetes
2016English

Real World Outcomes of Adding Rapid-Acting Insulin Versus Switching to Analog Premix Insulin Among US Patients With Type 2 Diabetes Treated With Insulin Glargine

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2013English

Insulin/Carbohydrates Ratio During the First 6‐month Therapy With Insulin Degludec in a Paediatric Population With Type 1 Diabetes Previously Treated With Insulin Glargine. An Observational Longitudinal Study

Endocrinology, Diabetes & Metabolism
2020English

Intensive Insulin Titration With Insulin Glargine in Insulin-Naive Type 2 Diabetic Patients in Turkey: LANTIT Study

Turkish Journal of Endocrinology and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2015English

Cost-Effectiveness of Insulin Degludec Compared With Insulin Glargine for Patients With Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Greater Suppression of Glucagon, Lipolysis and Ketogenesis With Insulin Glargine U300 as Compared to Glargine U100 in Type 1 Diabetes Mellitus

Diabetes Technology and Therapeutics
MedicineEndocrinologyMedical Laboratory TechnologyMetabolismDiabetes
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy